Why is dexamethasone not recommended for treating deruxtecan‑related interstitial lung disease, and why are prednisolone (or prednisone) or intravenous methylprednisolone preferred?

Why Dexamethasone is Not Recommended for Deruxtecan-Related ILD

Dexamethasone is avoided in deruxtecan-related interstitial lung disease because prednisolone (or prednisone) and methylprednisolone are the established corticosteroids for managing drug-induced and immune-related pneumonitis, while dexamethasone is primarily reserved for cytokine release syndrome and specific oncologic emergencies.

The Corticosteroid Selection Rationale

The choice of corticosteroid matters significantly in ILD management. While no guideline explicitly states "never use dexamethasone for deruxtecan-ILD," the established treatment paradigm for drug-induced and immune-related pneumonitis consistently employs prednisolone/prednisone or methylprednisolone 1.

Standard Treatment Protocol for Drug-Induced ILD

For grade 2 immune-related ILD, 1 mg/kg/day prednisolone (or equivalent) is the recommended starting dose. For grade 3 ILD, 1-2 mg/kg/day methylprednisolone IV or equivalent should be initiated, with tapering over 4-6 weeks for grade 2 and 6-8 weeks for grade 3 1.

The deruxtecan-related pneumonitis literature specifically describes treatment with corticosteroids (withholding drug with or without corticosteroids in 87% of cases), but does not specify dexamethasone as the agent of choice 2. The cryptogenic organizing pneumonia (COP) pattern—the most common presentation (72% of cases)—responds to standard corticosteroid regimens using prednisolone or methylprednisolone 2.

When Dexamethasone IS Used

Dexamethasone has specific, well-defined roles in oncology:

• Cytokine release syndrome: Dexamethasone 10 mg IV every 6-12 hours for grade 3-4 CRS 3
• Cerebral edema: 10 mg IV initially, followed by 4 mg every 6 hours 4, 5
• Acute allergic reactions: Short-course protocols 5

These indications are distinct from drug-induced pneumonitis.

Pharmacologic Considerations

Methylprednisolone and prednisolone have established dosing protocols, pharmacokinetics, and safety profiles specifically for ILD treatment 4, 6. Methylprednisolone 1000 mg IV for 3 days followed by low-dose prednisolone (10 mg/day) has demonstrated multidimensional efficacy in CTD-ILD with improvements in FVC, DLCO, and exercise capacity 6.

Dexamethasone's longer half-life (36-54 hours vs. 12-36 hours for prednisolone) and more potent mineralocorticoid-sparing effects make it less suitable for the prolonged, tapered courses required in ILD management 4, 5.

Critical Clinical Pitfalls

• The AIP/ARDS pattern of deruxtecan-ILD (11% of cases) carries higher mortality risk and requires immediate aggressive treatment with established protocols 2
• Earlier onset pneumonitis (median 17.9 weeks with AIP/ARDS pattern vs. 32.7 weeks with COP pattern) demands rapid recognition and appropriate corticosteroid selection 2
• If no improvement occurs within 72 hours of corticosteroid therapy, escalation to tocilizumab (8 mg/kg), infliximab (5 mg/kg), or IVIG should be considered 1

Treatment Algorithm for Deruxtecan-ILD

1. Immediately discontinue deruxtecan
2. Grade 2: Start prednisolone 1 mg/kg/day PO
3. Grade 3-4: Start methylprednisolone 1-2 mg/kg/day IV
4. Monitor response at 72 hours—if no improvement, add immunosuppressive agents
5. Taper slowly over 4-8 weeks depending on severity
6. Never use dexamethasone as first-line unless treating concurrent CRS or cerebral edema

The evidence consistently supports prednisolone/prednisone and methylprednisolone as the corticosteroids of choice for drug-induced ILD, with dexamethasone reserved for its specific oncologic indications 1, 4, 2, 6.